Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Atea Pharmaceuticals, Inc. Director's Dealing 2021

Jun 21, 2021

33577_dirs_2021-06-21_ba140fb5-025b-4f99-a8d2-1bab26135ab9.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Atea Pharmaceuticals, Inc. (AVIR)
CIK: 0001593899
Period of Report: 2021-06-18

Reporting Person: BERGER FRANKLIN M (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-06-18 Stock Option (Right to Buy) $23.39 A 34025 Acquired 2031-06-17 Common Stock (34025) Direct

Footnotes

F1: The option vests and becomes exercisable in twelve (12) equal monthly installments following June 18, 2021, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date.